Key Takeaways Addressing operational delays and administrative complexities in gene therapy could enhance revenue by quickly converting demand into treated patients. Expanding into LGMD and siRNA platforms diversifies revenue, potentially boosting earnings and financial stability.Read more
Key Takeaways Growing adoption of genetic testing, payer acceptance, and expanded infusion networks are driving revenue growth, pricing power, and increased patient access to therapies. Pipeline expansion, external collaborations, and manufacturing scale are positioning the company for diversified growth, improved margins, and long-term earnings gains.Read more
Key Takeaways Regulatory scrutiny and operational delays threaten timely access, increase compliance costs, and could pressure margins despite a favorable innovation climate and growing patient base. Overreliance on key products, delayed capacity expansion, and high upfront investments heighten risks of market saturation, revenue concentration, and sustained operating losses.Read more
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children’s Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
